CD274 and neoplasm: Additionally, the synergistic effect of GPX4 inhibitors in combination with anti-PD-1/PD-L1 therapy has shown increased anti-tumor immune response and tumor inhibition.361 Exploring the potential integration of the newly developed effective GPX4 inhibitor JKE-1674 with anti-PD-1/PD-L1 treatment, which enhances in vivo drug metabolism, presents an enticing opportunity.